Oncology Groups Respond to CMS’ Proposals for Payment Cuts
Provoking consternation from oncology groups, the Centers for Medicare & Medicaid Services (CMS) has proposed a slate of changes that would reduce payment for some forms of patient evaluation and management (E/M) and reduce the payment margin over wholesale acquisition cost (WAC) for Medicare Part B drugs.
